SynthesisFrontiers in oncology2026
Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunogenic cell death (ICD) represents a pivotal concept linking tumor cell demise with the activation of adaptive antitumor immunity. Since the concept was formalized around 2005, ICD has substantially reshaped research in tumor immunology and cancer therapy. However, bibliometric mapping and structured interpretation of the influential literature that has shaped this field remain limited. Methods: This bibliometric analysis, supplemented by structured narrative interpretation, used the Web of Science Core Collection and Scopus to identify the 100 most-cited ICD-related publications. Publication characteristics, citation patterns, journals, authors, institutions, countries/regions, and keywords were extracted and standardized. VOSviewer and CiteSpace were employed to construct collaboration networks, perform keyword co-occurrence and clustering analyses, and identify research hotspots and thematic evolution over time. Results: The top 100 most-cited ICD publications were published between 2005 and 2023. Within this highly cited publication set, more included papers were published after 2011, and the largest number of top-cited publications appeared in 2019. Highly cited studies were dominated by contributions from the United States and Western Europe, particularly France, with strong international collaboration networks. A small core of authors and institutions accounted for a substantial proportion of influential output. Keyword and burst analyses revealed a clear evolution from early work defining ICD hallmarks and antigen presentation mechanisms toward later integration with immunotherapy, nanomedicine, phototherapy, and engineered delivery platforms. Conclusion: Over the past two decades, ICD research has evolved from conceptual and mechanistic foundations toward a multidisciplinary framework with increasing relevance to tumor immunology, immunotherapy, and combination cancer therapy. Future progress will depend on function-based validation of immunogenicity, microenvironment-aware biomarkers, and rational therapeutic combinations to enhance clinical translatability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.